BACKGROUND: The national comprehensive cancer network (NCCN) guidelines has recently recognized total neoadjuvant therapy (TNT) as an acceptable option in patients with T3 and any N rectal cancer. Previous studies suggested that patients who received chemotherapy prior to conventional preoperative chemoradiation (CRT) and surgery allowed patients to receive more of their planned treatment with a better toxicity profile and increase in pathological response. However, those studies used a long course of FOLFOX or used capecitabine and oxaliplatin as induction regimen. We are conducting a phase 2 prospective clinical trial to evaluate the use of 6 cycles of FOLFOX as TNT in patients with T2-T3/N0-N+.

PATIENTS AND METHODS: Patients with T2-T3/N0-N+ enrolled on our phase 2 prospective trial were included for this analysis. Patients received six cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) which was administered every two weeks. After a 3 weeks of recovery period patient then received conventional CRT with 5FU or capecitabine. All patients got MRI and endorectal ultrasound (ERUS) at baseline, after completing FOLFOX 3-months regimen and after finishing conventional CRT. Patients underwent either full thickness local excision or total mesorectal resection depending on their tumor response to neoadjuvant therapy. The time interval between completion of radiation therapy and surgery ranged between 7-12 weeks.

RESULTS: A total of 10 patients completed the chemotherapy and CRT treatment regimen. 9 patients proceeded to surgery and the 10th patient is scheduled for surgery.
down-staging by MRI or ERUS was shown in 9 out of 10 patients with only six cycles of FOLFOX. Complete clinical response was achieved in 6 patients as evident by ERUS/MRI of the pelvis after 3 months of FOLFOX before CRT. Complete pathological response was found in 4 out of 9 patients (44%), in addition 4 other patients had significant albeit not complete pathological response.

CONCLUSION:
This study suggests that adding only six cycles of neoadjuvant FOLFOX before CRT improved clinical and pathological downstaging of T2-T3/N0-N+ rectal adenocarcinoma and may facilitate organ preservation surgery. This is strategy need to be investigated in larger phase III trial to validate these findings.
**PLEASE NOTE: Both forms must be completed and uploaded by the Primary Author, on behalf of all of the Authors, listed on the abstract in order to be considered.**

<table>
<thead>
<tr>
<th>PRIMARY AUTHOR’S FULL NAME and CREDENTIALS: Ahmed Abdalla</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Are you currently participating in, have participated in within the past 12 months, or do you expect to participate in funded or unfunded research on a technology, process, or product development within the next 12 months, or are you the Principal investigator for a project related to the research discussed in your abstract?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization, role and compensation:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>2. Are you currently participating, have participated in the past 12 months, or expect to participate as an advisory board member, speakers bureau member, expert witness, or consultant for an entity that could be viewed as having the potential to influence the content of your abstract within the next 12 months?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization, role and compensation:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>3. Do you currently hold, have you held in the past 12 months, or do you expect to hold in the next 12 months a paid position or serve on a governing board in a business engaged in commercial or research activities related to the content of your abstract?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization and role:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>4. Currently, or in the past 12 months, have you or has any member of your immediate family become a beneficial owner of any equity that would be financially advantaged or disadvantaged by the discussion in your abstract?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization and role:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>5. In the past 12 months, have you or has any member of your immediate family been employed by an entity that could be viewed as having the potential to influence the content of your abstract?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization and role:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>6. Could the discussion of your abstract have a direct and substantial (&gt; $10,000) economic impact on you or on others with whom you have a personal or professional relationship?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization, role, and compensation:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>7. Do you or do members of your immediate family receive royalty income or have the right to receive future royalties under a patent license or copyright where your abstract is directly related to the licensed technology or work?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization, role and compensation:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>8. Do you have any other organizational affiliations, activities, or other interests, including equity, which could significantly impair your objectivity in your abstract?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, please list organization and role:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>9. <strong>ON BEHALF OF ALL CO-AUTHORS:</strong> As the Primary Author, it is your responsibility to obtain and report any pertinent disclosure information for all of the co-Authors listed on the abstract. Does any of the co-Authors listed on the abstract have any disclosure information to report?</td>
</tr>
<tr>
<td>NO ☒</td>
</tr>
<tr>
<td>If <strong>YES</strong>, list the names of the co-Author(s) and all disclosure information:</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

In submitting this statement, I affirm that I will comply with any conditions or restrictions adopted by NCCN to manage, reduce, or eliminate any identified conflict of interest.

**SIGNATURE:**

(name cannot be typed; an authentic longhand or electronic signature **MUST** be provided)

**DATE:** 11/7/2018
Abstract Title: Induction chemotherapy followed by chemoradiation and trans-anal full thickness local excision or total mesorectal Resection in patients with T2-T3/NO-N+ Adenocarcinoma of the Rectum; preliminary results of phase 2 prospective clinical trial.

Author(s): Ahmed Abdalla MD, Amr Aref, Amer Alame, Mohamad Barawi, MD, Daniel Ma MD, Zyad Kafri MD

Copyright: In consideration of publication of the article in JNCCN, the primary Author, on behalf of all the Authors, hereby assign the National Comprehensive Cancer Network (NCCN) and its successors all right, title, and interest in and to the article, including but not limited to all copyright rights, throughout the world and for all terms of protection.

The primary Author, on behalf of all the Authors, warrant that they are the sole authors and owners of the article (except for those portions thereof, such as illustrations, tables, or quotations, that are reproduced from other sources), that all coauthors are aware of the Abstract contents, support its data, and have given approval for publication; that the abstract has never been published; that it contains no matter infringing on the copyright or other proprietary right of any other person; that it contains no injurious or libelous matter; and that they will hold harmless and indemnify NCCN and Harborside Press and their employees against any claims or proceedings instituted on the grounds that the Work infringes such rights or contains such hurtful matter. Regarding material copied from other sources, the foregoing warranty means that the Authors have obtained or will obtain licenses from the copyright owners of such material, using forms provided by NCCN.

This instrument, if signed after publication of the article, expresses the original intent of the Authors, and shall be given effect retroactively to the date of acceptance of the Work for publication, so that from and after publication, NCCN shall have been the owner of all rights in the work and solely entitled to enforce such rights worldwide.

Author(s) Signature(s) ___________________________ Date: 11/7/2018

(name cannot be typed; an authentic longhand or electronic signature MUST be provided)

US Federal Employees: I was an employee of the US federal government when this work was conducted and prepared for publication; therefore, it is not protected by the Copyright Act and there is no copyright. Thus, ownership cannot be transferred.

Author(s) Signature(s) ___________________________ Date: ________________________

(name cannot be typed; an authentic longhand or electronic signature MUST be provided)
CONFLICT OF INTEREST DECLARATION/AUTHOR AGREEMENT FORM

This form must be completed and included with transmission in order for JNCCN to consider your manuscript for publication.

Title: Induction chemotherapy followed by chemoradiation and trans-anal full thickness local excision or total mesorectal Resection in patients with T2-T3/NO-N+ Adenocarcinoma of the Rectum; preliminary results of phase 2 prospective clinical trial.

Author Names (full names with degrees): Ahmed Abdalla MD, Amr Aref, Amer Alame, Mohamad Barawi, MD, Danny Ma MD, Zyad Kafri MD

Please select one of the following:

☒ We have no conflict of interest to declare.

☐ We have the following conflict(s) of interest to declare:

Click here to enter text.

Completion of this Agreement certifies that

❖ all Authors listed have seen and approved the manuscript being submitted,
❖ the article is the Authors' original work,
❖ the article or research has not been submitted for publication nor has it been published in whole or in part elsewhere*,
❖ all Authors are prepared to assign copyright to JNCCN upon acceptance of the manuscript,
❖ the corresponding Author shall bear full responsibility for the submission on behalf of all Co-Authors, and
❖ all Authors listed on the title page have contributed significantly to the work.
*excepting abstracts published as part of meeting materials

Author signature: Ahmed Abdalla

☑ Please check this box if you are submitting this on behalf of all authors.
**TITLE:**

Induction chemotherapy followed by chemoradiation and trans-anal full thickness local excision or total mesorectal Resection in patients with T2-T3/NO-N+ Adenocarcinoma of the Rectum; preliminary results of phase 2 prospective clinical trial.

**LIST NAMES, DEGREES, ACADEMIC POSITIONS (eg, Associate Professor, Assistant Professor, Fellow), AND AFFILIATIONS FOR EACH AUTHOR:**

Ahmed Abdalla MD Hematology and oncology fellow St. John Hospital.

Amr Aref, MD assistant professor radiation oncology St. John Hospital.

Amer Alame, colon and rectal surgeon St. John Hospital.

Mohamad Barawi, MD; Assistant Professor of Gastroenterology St. John Hospital.

Danny Ma, MD Radiation Oncologist St. John Hospital.

Zyad Kafri MD assistant Professor Hematology and oncology fellowship program director St. John Hospital.

(Note: Abstracts have a strict 2500 character limit (includes spaces and punctuation); any abstract exceeding this limit will not be considered)

**ABSTRACT:**

**BACKGROUND:**
The national comprehensive cancer network (NCCN) guidelines has recently recognized total neoadjuvant therapy (TNT) as an acceptable option in patients with T3 and any N rectal cancer. Previous studies suggested that patients who received chemotherapy prior to conventional preoperative chemoradiation (CRT) and surgery allowed patients to receive more of their planned treatment with a better toxicity profile and increase in pathological response. However, those studies used a long course of FOLFOX or used capecitabine and oxaliplatin as induction regimen. We are conducting
a phase 2 prospective clinical trial to evaluate the use of 6 cycles of FOLFOX as TNT in patients with T2-T3/N0-N+.

PATIENTS AND METHODS:
Patients with T2-T3/N0-N+ enrolled on our phase 2 prospective trial were included for this analysis. Patients received six cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) which was administered every two weeks. After a 3 weeks of recovery period patient then received conventional CRT with 5FU or capecitabine. All patients got MRI and endorectal ultrasound (ERUS) at baseline, after completing FOLFOX 3-months regimen and after finishing conventional CRT. Patients underwent either full thickness local excision or total mesorectal resection depending on their tumor response to neoadjuvant therapy. The time interval between completion of radiation therapy and surgery ranged between 7-12 weeks

RESULTS:
A total of 10 patients completed the chemotherapy and CRT treatment regimen. 9 patients proceeded to surgery and the 10th patient is scheduled for surgery. Clinical down-staging by MRI or ERUS was shown in 9 out of 10 patients with only six cycles of FOLFOX. Complete clinical response was achieved in 6 patients as evident by ERUS/MRI of the pelvis after 3 months of FOLFOX before CRT. Complete pathological response was found in 4 out of 9 patients (44%), in addition 4 other patients had significant albeit not complete pathological response.

CONCLUSION:
This study suggests that adding only six cycles of neoadjuvant FOLFOX before CRT improved clinical and pathological downstaging of T2-T3/N0-N+ rectal adenocarcinoma and may facilitate organ preservation surgery. This is strategy need to be investigated in larger phase III trial to validate these findings.